Recipharm AB: Recipharm Publishes Annual Report 2014

Regulatory News:

Recipharm (STO: RECI)

Recipharm publishes today its Annual report for 2014 on www.recipharm.com. The Annual report is available in Swedish and English. The English version is also integrated with a review of the Company’s business.

The complete Annual report in English is also attached to this announcement.

Recipharm’s Annual General Meeting is held on 7 May 2015.

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 16 April 2015, at 09:00 am CET.

About Recipharm Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

Recipharm AB (publ)

Corporate identity number 556498-8425

Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

http://mb.cision.com/Main/9273/9756605/367174.pdf

This information was brought to you by Cision http://news.cision.com